BioLegend spends a considerable amount of effort in creating new antibodies for research. The majority of these new antibody products are monoclonal antibodies (mAb) produced from hybridomas. Clones of these hybridomas are carefully selected based on a number of criteria including robust growth and efficient production of a single clone of antibody that is specific to the intended target. The best clones move on to applications testing.
As manufacturers are starting to produce recombinant antibodies, these would need to be validated and addressed in the same ways as hybridoma-derived antibodies. A mAb produced from an engineered DNA source is not inherently more specific than one produced from a traditional hybridoma. However, genetic modifications to the overall structure could potentially convey improved performance in assays.